filmov
tv
Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans
Показать описание
CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and plans and milestones for Algernon's DMT stroke research program in 2024 and beyond.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is the parent company of a private subsidiary called Algernon NeuroScience, which is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury and has an active research program for chronic kidney disease.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is the parent company of a private subsidiary called Algernon NeuroScience, which is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury and has an active research program for chronic kidney disease.
0:40:36
0:08:14
0:16:39
0:08:16
0:03:51
0:03:25
0:03:11
0:01:05
0:44:21
0:07:22
0:00:52
0:05:15
0:32:29
0:07:44
0:06:56
0:08:12
0:01:49
0:01:15
0:03:39
0:04:46
0:04:26
0:04:13
0:04:41
0:05:36